About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to editors

  1. ABPI has an ongoing collaboration with The National Centre for the Replacement, Refinement and Reduction of animals in research (NC3Rs), which is now in its 11th year https://www.nc3rs.org.uk/
  2. For more information on procedures and severity classifications, see Understanding Animal Research: http://www.understandinganimalresearch.org.uk/how/understanding-animal-procedures/
  3. The recent peer-reviewed publication shows that the use of in vitro, non-animal, techniques in the pharmaceutical industry has increased rapidly in recent years, demonstrating the industry's commitment to the 3Rs. Goh et al (2015) Toxicol. Res. 4, 1297-1307. Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980–2013.

Media enquiries


+44 (0) 20 7747 7147​​